Publicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (10)

2024

  1. A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

    Clinical Cancer Research, Vol. 30, Núm. 4, pp. 695-702

2023

  1. Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer

    Cancer Science, Vol. 114, Núm. 3, pp. 1026-1036

2022

  1. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

    The Lancet Oncology, Vol. 23, Núm. 5, pp. 659-670

2021

  1. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 5, pp. 665-677

  2. Safety and activity of the TGFβ receptor i kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2020

  1. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer

    New England Journal of Medicine, Vol. 383, Núm. 23, pp. 2207-2218

2011

  1. Therapy innovations: Tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors

    Cancer and Metastasis Reviews, Vol. 30, Núm. SUPPL. 1

2004

  1. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy

    Journal of Clinical Oncology, Vol. 22, Núm. 8, pp. 1480-1490

2002

  1. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors

    Oncologist, Vol. 7, Núm. 6, pp. 531-538

  2. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: Associations with clinical characteristics, pathophysiological variables and toxicity

    Cancer Chemotherapy and Pharmacology, Vol. 50, Núm. 4, pp. 309-319